- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00442910
Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women
Phase 1 Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel™) Applied Vaginally in Sexually Active Young Women
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Women continue to comprise a growing proportion of the new HIV infections around the world. A growing body of data suggests that a safe and effective topical microbicide will be a real option of prevention for women in the future. The purpose of this study is to assess the safety and acceptability of 3% SPL7013 Gel when administered intravaginally, twice daily for 14 consecutive days in healthy, sexually-active, HIV-uninfected women.
The expected duration of this study for each participant is 21 days. Study participants will be randomly assigned to one of two arms. Participants in Arm 1 will apply 3.5 g of SPL7013 gel intravaginally twice daily for 14 consecutive days. Participants in Arm 2 will apply a placebo gel intravaginally twice daily for 14 consecutive days. Starpharma produces SPL7013 gel (VivaGel) and will provide it for this study.
After enrollment, participants will attend three study visits. These visits will occur on Days 7, 14, and 21. A follow-up safety visit will occur if necessary. Medical and menstrual history, targeted physical exam, urine and blood collection, cervical swabs, and vaginal smears will occur at all visits. A colposcopy will occur at least once. On Day 2, participants will take part in a phone assessment.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
San Juan, Puerto Rico, 00936-5067
- University of Puerto Rico
-
-
-
-
Florida
-
Tampa, Florida, United States, 33606
- University of South Florida
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213-3180
- Center for Family Planning Research, Magee-Womens Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HIV-uninfected
- General good health
- Normal Pap result within 12 months prior to study entry
- Predictable menstrual cycle with at least 21 days between menses
- Sexually active
- Willing to use effective methods of contraception for the duration of the study. More information on this criterion can be found in the protocol.
- Willing to abstain from oral-vaginal and penile-anal intercourse for the duration of the study
- Willing to not use other intravaginal products and/or devices for 72 hours prior to study entry through Week 3
- Agree to have partner use condoms provided by study for each act of intercourse during study participation
- Willing to undergo colposcopy if determined necessary by investigator
- Agree to not participate in other drug or device studies during study participation
Exclusion Criteria:
- History of adverse reaction to latex or to any component of the study products
- History of male sex partner having an allergic reaction to latex
- Any abnormal finding on physical or pelvic examination
- Sexually transmitted infection (STI) or reproductive tract infection. More information on this criterion is available in the protocol.
- Diagnosed with STI within 6 months prior to study entry
- Use of oral and/or vaginal preparations of antibiotic or antifungal medications within 30 days prior to study entry
- Gynecological surgical procedure within 90 days prior to study entry
- Certain abnormal laboratory values. More information on this criterion is available in the protocol.
- Received non-therapeutic intravenous drugs within 12 months prior to study entry
- Any social or medical condition, that, in the opinion of the investigator, would interfere with the study
- Pregnant of breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 3% SPL7013
Intravaginal application of 3.5 g SPL7013 gel twice daily for 14 days
|
3% vaginal gel
Other Names:
|
Placebo Comparator: Placebo for SPL7013 Gel
Intravaginal application of 3.5 g placebo gel twice daily for 14 days
|
Placebo for SPL7013 gel
|
Placebo Comparator: HEC Placebo Gel
Intravaginal application of 3.5 g HEC placebo gel twice daily for 14 days
|
HEC Placebo gel intravaginally bd for 14 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Incidence of abnormal genital symptoms and/or pelvic exam findings
Time Frame: Throughout study
|
Throughout study
|
Occurrence of adverse events and/or abnormal laboratory values
Time Frame: Throughout study
|
Throughout study
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in vaginal microflora
Time Frame: Throughout study
|
Throughout study
|
Proportion of participants who report an 80% or greater adherence rate
Time Frame: At Day 7 and Day 14
|
At Day 7 and Day 14
|
Proportion of participants who say they would be very likely to use the study product in the future
Time Frame: At Day 14
|
At Day 14
|
Reported positive and negative aspects of using study product
Time Frame: Throughout study
|
Throughout study
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Ian McGowan, MD, PhD, University of California Geffen School of Medicine
Publications and helpful links
General Publications
- Balzarini J, Van Damme L. Microbicide drug candidates to prevent HIV infection. Lancet. 2007 Mar 3;369(9563):787-797. doi: 10.1016/S0140-6736(07)60202-5.
- Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine. 2007;2(4):561-6.
- McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, Husnik M, Livant E, Price C, Jacobson C; MTN-004 Protocol Team. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel) in sexually active young women (MTN-004). AIDS. 2011 May 15;25(8):1057-64. doi: 10.1097/QAD.0b013e328346bd3e.
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- MTN-004; SPL7013-006
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
-
King's College LondonUniversity of ReadingCompletedHealthy | Healthy AgingUnited Kingdom
Clinical Trials on 3% SPL7013 Gel (VivaGel)
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV Infections | HSV-2 Genital HerpesAustralia
-
Starpharma Pty LtdCompleted
-
Starpharma Pty LtdCompleted
-
Starpharma Pty LtdNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Starpharma Pty LtdCompletedRecurrent Bacterial Vaginosis (BV)
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States, Puerto Rico, Canada
-
Starpharma Pty LtdCompletedBacterial VaginosisUnited States, Bulgaria, Czechia, Hungary, Ukraine, United Kingdom
-
Lakewood-Amedex IncPrimeVigilance; Professional Education and Research InstituteTerminated